- Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEFQiu, Mei*; Ding, Liang-Liang; Zhan, Ze-Lin; Zhou, Hai-RongESC Heart Failure, 2021, 8(2): 1722-1724.被引 2
- The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failureHeerspink, J. L.; Wheeler, D. C.; Vart, P.; Jongs, N.; Hou, F. F.; Langkilde, A. M.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Toto, R. D.; Chertow, G. M.; Stefansson, B. V.; McMurray, J. J. V.
- THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR <30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIALChertow, G.; Vart, P.; Jongs, N.; Toto, R.; Gorriz, J. L.; Hou, F. F.; Mcmurray, J.; Correa-Rotter, R.; Rossing, P.; Sjostrom, C. D.; Stefansson, B. V.; Langkilde, A. M.; Wheeler, D. C.; Heerspink, H. J. L.
期刊论文
Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF
2被引9阅读
